SecBot SecBot

ARTV

Artiva Biotherapeutics, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001817241 Biotech & Drug Discovery
$4.01 +0.05 (+1.26%)
Nov 13 4:00 PM ET · prev $3.96
Market cap
$195.8M
Micro cap
Consensus
Buy
58% Buy or better · 12 analysts
Median target
$19.50
+386% · range $4.00–40.00
Next earnings
Nov 18
in 2 days · EPS est. −$0.53
1 year
+14.2%
from $3.51 · Nov 17
30 days
−31.9%
from $5.89
52-week range
$3.07–13.39
−70% from high · low Dec 10
Avg volume 20D
1.36M
Oct 27 spike 8.67M
Short interest
2.95M
≈6.0% of shares · +7.9%
Days to cover
1.8
at average volume
Insider net
+$1.1M
1 buyer · 4 sellers · since Jul 21
New fund stakes
0
Q3 2026 13F · 0 exits
SecBot read BEARISH 12 reports · 90 days
Balance 5 bearish · 0 bullish · 7 neutral oldest → newest, height = score
Avg score ·High conf. 7/12 ·Next Earnings date, Nov 18, 2026

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersMIXED

    1 insider bought $3.5M at an average $9.82. 4 insiders sold $2.3M. Price is 59% below their cost.

  • InstitutionsBULLISH

    Q3 2026: 17 added (0 new), 6 trimmed or exited.

  • AnalystsBULLISH

    7 of 12 rate it Buy or better. Median target $19.50 (+386%).

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.522 → −$0.534 over 90 days.

  • Short sellersSTEADY

    Short interest +7.9% to 2.95M shares. 1.8 days to cover, ≈6.0% of shares.

  • TrendDOWNTREND

    40% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.DOUBLED1,511,266$10.8M
GEODE CAPITAL MANAGEMENT, LLCADD532,389$3.8M
STATE STREET CORPDOUBLED339,761$2.4M
VANGUARD PORTFOLIO MANAGEMENT LLCDOUBLED259,504$1.8M
UBS Group AGTRIM103,440$736.5K
Squarepoint Ops LLCDOUBLED74,681$531.7K
RENAISSANCE TECHNOLOGIES LLCTRIM74,078$527.4K
MORGAN STANLEYDOUBLED40,583$289.0K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

12 analysts
Buy 58% rate it Buy or better
Strong Buy2Buy5Hold5Sell0Strong Sell0
12-month targets · 4 analysts

Price is inside the target range. Median implies +386%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Oct 29, 2026Jefferies
DOWNGRADE
DOWNGRADEHold
Oct 27, 2026Needham
DOWNGRADE
DOWNGRADEHold
Oct 27, 2026Wedbush
DOWNGRADE
DOWNGRADENeutral
Oct 2, 2026Cantor Fitzgerald
REITERATE
REITERATEOverweight
Jun 8, 2026Needham
REITERATE
REITERATEBuy

Insider ledger

Form 4
$3.5M
bought · 1 insider
$2.3M
sold · 4 insiders
−59.1%
vs their $9.82 cost
DateInsiderTypeValue
Nov 2, 2026
Banerjee Subhashis
Chief Medical Officer
Nov 2, 2026
SELL$4.6K
Nov 2, 2026
Aslan Fred
Chief Executive Officer
Nov 2, 2026
SELL$260.0K
Nov 2, 2026
Horan Christopher
Chief Tech Operations Officer
Nov 2, 2026
SELL$43.6K
Nov 2, 2026
Bush Jennifer
COO, CLO, Compliance Officer
Nov 2, 2026
SELL$35.3K
Oct 6, 2026
Aslan Fred
Chief Executive Officer
Oct 6, 2026
SELL$168.9K
Oct 5, 2026
Horan Christopher
Chief Tech Operations Officer
Oct 5, 2026
SELL$70.7K
Oct 5, 2026
Banerjee Subhashis
Chief Medical Officer
Oct 5, 2026
SELL$7.5K
Oct 5, 2026
Bush Jennifer
COO, CLO, Compliance Officer
Oct 5, 2026
SELL$57.2K

Earnings setup

Estimates
Nov 18
reports in 2 days
−$0.53
EPS estimate, this quarter
−2%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.53-$0.56–-$0.47+0.0%$0.00
Next Q-$0.17-$0.20–-$0.13+71.3%$0.00
Current FY-$2.71-$3.01–-$2.30-7.8%$0.00
Next FY-$1.53-$3.31–-$0.19+41.2%$0.00

Short side

FINRA· Oct 30, 2026
2,953,973
shares short
+7.9%
vs prior settlement
1.8
days to cover
≈6.0%
of shares outstanding
Trading halts
Oct 27, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 12, 2026 Other
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Artiva Biotherapeutics, Inc. - ARTV
NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
Nov 9, 2026 SEC
Artiva Biotherapeutics filed an amended 8-K providing cost estimates for its wind-down, which includes discontinuing…
8-K/A · Impact 7/10
Nov 3, 2026 SEC
CEO and CMO sold shares days after the company discontinued its sole pipeline candidate, announced a 94% workforce…
CLUSTER · Impact 6/10
Nov 2, 2026 Insider
Banerjee Subhashis sold 1,110 shares
Chief Medical Officer @ $4.18 ($4.6K)
Nov 2, 2026 Insider
Aslan Fred sold 62,178 shares
Chief Executive Officer @ $4.18 ($260.0K)
Nov 2, 2026 Insider
Horan Christopher sold 10,423 shares
Chief Tech Operations Officer @ $4.18 ($43.6K)
Oct 27, 2026 SEC
Artiva Biotherapeutics is discontinuing all development of its sole pipeline candidate AlloNK (AB-101) after updated…
8-K · Impact 6/10
Sep 30, 2026 Inst.
BlackRock, Inc. · DOUBLED
1,511,266 shares ($10.8M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Upcoming
Recent
Nov 12, 2026
Press release
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Artiva Biotherapeutics, Inc. - ARTV
NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Artiva Biotherapeutics, Inc. ("Artiva" or…
Oct 27, 2026
Trading halt
Halt Resumed: ARTV, trading resumed after T5 (Single Stock Trading Pause)
Halted 2026-10-27T11:25:00.000Z | Resumed 2026-10-27T11:50:00.000Z
Oct 27, 2026
Press release
Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK®
Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK®
Oct 27, 2026
Trading halt
Trading Halt: ARTV, T5 (Single Stock Trading Pause)
Artiva Biotherapeutics, Inc CS | Market: NASDAQ | Code: T5, Single Stock Trading Pause
Oct 2, 2026
Press release
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026

SecBot reports

28 filings · 5 press releases · 10 bullish · 7 bearish · 11 neutral
All ARTV filing & press-release reports (33)